Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
(Approval lapsed) BEYFORTUS nirsevimab 50mg/0.5mL injection solution in pre-filled syringe (Germany)
Section 19A approved medicine
(Approval lapsed) BEYFORTUS nirsevimab 50mg/0.5mL injection solution in pre-filled syringe (Germany)
Section 19A approval holder
Sanofi-Aventis Australia Pty Ltd ABN 31 008 558 807
Phone
1800 818 806
Approved until
Status
Expired
Medicines in short supply/unavailable
BEYFORTUS nirsevimab 50mg in 0.5mL solution for injection prefilled syringe - ARTG 397898
Indication(s)
BEYFORTUS is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in:
- Neonates and infants born during or entering their first RSV season.
- Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
BEYFORTUS should be used in accordance with official recommendations.
Images
